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Abstract
Background: Histone deacetylase inhibitors (HDACi) exert multiple cytotoxic actions on cancer cells. Currently,
different synthetic HDACi are in clinical use or clinical trials; nevertheless, since both pro-invasive and anti-invasive
activities have been described, there is some controversy about the effect of HDACi on melanoma cells.
Methods: Matrigel and Collagen invasion assays were performed to evaluate the effect of several HDACi (Butyrate,
Trichostatin A, Valproic acid and Vorinostat) on two human melanoma cell line invasion (A375 and HT-144). The
expression of N- and E-Cadherin and the activity of the RhoA GTPase were analyzed to elucidate the mechanisms
involved in the HDACi activity.
Results: HDACi showed a pro-invasive effect on melanoma cells in vitro. This effect was accompanied by an
up-regulation of N-cadherin expression and an inhibition of RhoA activity. Moreover, the down-regulation of
N-cadherin through blocking antibodies or siRNA abrogated the pro-invasive effect of the HDACi and, additionally,
the inhibition of the Rho/ROCK pathway led to an increase of melanoma cell invasion similar to that observed with
the HDACi treatments.
Conclusion: These results suggest a role of N-cadherin and RhoA in HDACi induced invasion and call into question
the suitability of some HDACi as antitumor agents for melanoma patients.
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Abbreviations: EMT, Epithelial to mesenchymal transition; GFP, Green fluorescent protein; HAT, Histone acetyl
transferase; HDAC, Histone deacetylase; HDACi, Histone deacetylase inhibitor; HRP, Horseradish peroxidase;
TSA, Trichostatin A
Background
Gene expression in eukaryotic cells is epigenetically
regulated by the antagonistic activities of histone acetyl-
transferases (HATs) and histone deacetylases (HDACs).
Histone acetylation by HATs mediates the formation of
accessible chromatin regions and promotes gene expres-
sion, whereas histone deacetylation catalyzed by HDACs
leads to a repressive state due to chromatin compaction.
Given the capital function of these enzymes, their acti-
vities are tightly regulated.
The role of HDACs in cancer progression was first
demonstrated in acute promyelocytic leukemia [1] and is
currently known in many other tumor types, including
melanoma [2–5]. Therefore, HDACs have emerged as a
target for anticancer therapies and many authors have
focused their research on this issue. As a consequence, it
has been demonstrated that several HDAC inhibitors
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(HDACi) induce growth arrest, differentiation and apop-
tosis in different cancer cell lines [6–8]. Several HDACi
have been previously used in clinical trials with different
tumor types, including melanoma [9]. In a phase I/II
clinical trial of Valproic acid in combination with Topo-
isomerase I inhibitor, Karenitecin, 47 % of patients had
stable disease with median progression-free survival of
10.3 weeks versus 34 % with stable disease with median
progression-free survival of 7.9 weeks shown in patients
on a previous phase II study with Karenitecin as a single
agent [10]. In another phase I study with the HDACi
MS-275 disease stabilization and partial remission were
observed in patients with melanoma and other solid
tumors [11]. Phase I clinical trials of vorinostat in combi-
nation with other drugs have shown interesting results
on melanoma patients, with a significant percentage of
disease stabilization and tumor measurement reduction.
Nevertheless, no responses were shown under RECIST
criteria [12].
HDACi have also been associated with the epithelial-to-
mesenchymal transition (EMT) [13, 14], a process that
contributes to invasion and progression of cancer cells.
This process is characterized by the acquisition of an elon-
gated fibroblast-like morphology, inhibition of cell adhe-
sion and an increase of cell motility as one of its main
hallmarks [15, 16].
HDACi can be classified into several structural classes
including, in order of decreasing potency, hydroxamic
acids, cyclic peptides, benzamides and aliphatic acids.
Sodium butyrate is a fatty acid synthesized by intestinal
bacteria that inhibits the cell cycle through the activation
of the p21Waf1/Clip1 gene [17]. We have previously
shown that butyrate induces the apoptosis of melanoma
cells in a synergistic manner when combined with resvera-
trol [6]. In spite of the clear pro-apoptotic effect of butyr-
ate and other HDACi, its effect on the invasive capability
of cancer cells is still controversial. Some authors point to
butyrate as an inhibitor of invasion in cancer cells [18–20],
whereas others have observed the opposite result [16, 21].
Therefore, in order to characterize the effect of HDACi
on human melanoma cells, we have evaluated the invasive-
ness of two human melanoma cell lines (A375, derived
from a primary tumor, and HT-144, obtained from a
subcutaneous metastatic site) treated with a variety of
HDACi, two of them were hydroxamic acids (Trichostatin
A and Vorinostat) and the other two were aliphatic acids
(Butyrate and Valproic acid). We have also analyzed the
effect of these inhibitors on cadherin expression and RhoA
activity. Our results demonstrate that most HDACi pro-
mote melanoma cell invasion in vitro after 24 h. Moreover,
this pro-invasive response to HDACi could be mediated
by the E- to N-cadherin switch at the cell-cell adhesion
complexes and a decrease in the activity of RhoA small
GTPase.
Methods
Cell culture
A375 and HT-144 melanoma cell lines were purchased
from ATCC. Cells were grown in DMEM growth medium
supplemented with 10 % Fetal Bovine Serum, 1 % L-
Glutamine and 1 % Penicillin-Streptomycin. Cells were
maintained at 37 °C in an incubator with a 5 % CO2
humidified atmosphere, and were subcultured every 2–3
days with trypsin-EDTA solution.
Drug treatments
Melanoma cells were treated with 2 mM butyrate (Sigma-
Aldrich, St. Louis, MO), 100 nM TSA (Sigma-Aldrich, St.
Louis, MO), 1 mM valproic acid (Sigma-Aldrich, St. Louis,
MO) and 3 μM vorinostat (Selleckchem, Houston, TX).
In order to minimize the interference of apoptosis in the
quantification of cell invasiveness we have used low con-
centrations of HDACi among the standard range found in
the literature [6, 22–29]. The cells were exposed to the
HDACi during 24 h in all the experiments except if some-
thing different is specified.
Drug sensitivity assay
A375 and HT144 cells were seeded at 10,000 cells/well
and 5000 cells/well respectively in triplicate in 96-well
plates and treated for 24 h with varying concentrations
of Butyrate, TSA, Valproic acid and Vorinostat (Fig. 1).
After 24 h, relative viable cell numbers were determined
using the MTT viability Assay (Sigma), which measures
bioreduction of MTT into a soluble formazan that was
measured in a microplate reader at A540 nm.
Flow cytometric analysis of apoptosis
A375 melanoma cells were treated with HDAC inhibitors
as indicated above during 24 and 48 h, cells were then har-
vested, washed and stained using the apoptosis detection
kit Annexin V FITC of Immunostep (Salamanca, Spain)
according to the manufacturer’s recommendations. Sam-
ples were acquired on a Gallios flow cytometer (Beckman
Coulter, Brea, CA). Acquired samples were analyzed using
Kaluza software (Beckman Coulter, Brea, CA).
Matrigel invasion assay
Matrigel is an extracellular matrix component similar to
the basal membrane that separates epidermis and dermis
so we decided to use this assay to evaluate the invasive-
ness of a primary tumor derived cells (A375). We used
6.5 mm diameter Transwell inserts (Costar) with 8 μm
pore membranes. The membranes were coated with 35 μl
Matrigel (BD Biosciences) at 3 mg/ml in serum-free
DMEM and allowed to solidify in the incubator at 37 °C
for 2 h. Cells were detached, washed twice with PBS and
re-suspended in serum-free DMEM. 5×105 cells in 50 μl
were placed in the upper chamber with the corresponding
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Fig. 1 HDAC inhibitor sensitivity assay. The number of viable A375 cells (upper panel) was reduced by Butyrate 2 mM (by 3 %), TSA 100 nM (by 10 %),
Valproic acid 1 mM (by 15 %) and Vorinostat 3 μM (by 10 %) compared with the untreated control (set at 100 %). HT-144 cells (lower panel) were more
sensitive to HDACi and its viability was reduced by Butyrate 2 mM (by 13 %), TSA 100 nM (by 17 %), Valproic acid 1 mM (by 22 %) and Vorinostat 3 μM
(by 25 %). Cell number was determined after 24 h of treatment by the MTT proliferation assay (Sigma). Shown data correspond to representative
experiments carried out in triplicate and repeated twice. Values are expressed as the mean ± SD
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treatment, and the lower chamber was filled with 1 ml of
DMEM-10 % FBS. After a 24 h incubation period, the cells
that remained in the upper chamber were scraped away.
Cells in the lower surface of the membrane were stained
with Hoechst for 15 min. Pictures of the lower surface of
the insert were taken with a confocal microscope (Olympus
Fluoview FV500) using a 4× objective capturing the central
area of the membrane (9 mm2). Invading cell number was
quantified with the ImageJ software.
Collagen invasion assay
Type I collagen is the most abundant component of the
connective tissue of the dermis so it was used to analyze
the invasion of cells derived from a subcutaneous meta-
static site (HT-144). The type I collagen solution was
prepared mixing the following components at 4 °C: four
volumes of type I collagen (3.49 mg/ml), five volumes of
calcium-magnesium-free Hank’s balanced salt solution,
one volume of MEM (10×), one volume of 0.25 M
NaHCO3, 2.65 volumes of culture medium, and 0.3
volumes of 1 M NaOH. 1.25 ml of type I collagen solu-
tion was added to each well of six-well plates, homoge-
neously spread, and solidified for one hour at 37 °C on a
flat surface in a humidified atmosphere with 5 % CO2. 10
5
single cells suspended in 1 ml of culture medium with the
corresponding treatment were seeded on top of the type I
collagen gel and maintained at 37 °C in an incubator.
Cell morphology was studied and invasion was scored
after 24 h of incubation. The number of invasive and
noninvasive cells was counted in ten randomly selected
microscopic fields with a 20× objective using an inverted
phase contrast microscope (Nikon Eclipse Ti-S). The
invasion index was calculated as the ratio of the number
of invading cells, which showed dark protrusions in their
membrane, divided by the number of non-invasive cells
counted in each field. Then, control was set as 100 and
the other data relative to control. For the phalloidin stain-
ing collagen gels were fixed with 3 % paraformaldehyde,
permeabilized with 0.5 % Triton, and then incubated with
Phalloidin-TRITC and DAPI for 30 min. Actin cytoske-
leton images were taken with a confocal microscope
(Olympus Fluoview FV500).
Shape factor
Pictures of phalloidin stained HT-144 cells invading
collagen after 24 h of culture (with or without HDACi)
were taken with a confocal microscope (Olympus Fluoview
FV500) at low magnification (10× objective). Then shape
factor, or circularity factor, was measured with Image J as 4
πA/P2, with A being the area and P the perimeter of the
cell. Shape factor is measured from 0 to 1. A shape factor
of 1 corresponds to a round cell, as shape factor goes to
zero cells are assumed to be increasingly more spread. Ten
pictures of three independent experiments were evaluated
for each condition.
Protein extraction and Western Blot
Cells were lysed in 1× Laemmli buffer and protein con-
centrations were determined via Bio-Rad Rc-Dc protein
assay in accordance with the manufacturer’s instructions.
Twenty-five nanogram of proteins were transferred to
PVDF membranes. The membranes were probed with the
corresponding antibodies, incubated with diluted HRP-
linked secondary antibody and visualized by enhanced
chemiluminescence (ECL) in accordance with the recom-
mended procedure.
Immunoprecipitation
To study the function of cadherins we performed immu-
noprecipitation with α-catenin in order to precipitate
proteins in the cadherin/catenin complex from cell extracts
of untreated and HDACi treated (24 h) cultures. Immuno-
precipitation for α-catenin was carried out with magnetic
beads (Dynabeads M-280 Sheep anti- Rabbit IgG). Mag-
netic beads were incubated with α-catenin antibody
for 2–4 h at 4 °C. After antibody incubation, cell lysates,
made in NP40 lysis buffer (1 % NP40 PBSD+), were added
and incubated overnight at 4 °C. Then beads were washed
five times for 5 min and finally denatured in boiling Lae
mmli buffer (1 ml Laemmli 1.5×, 75 μl β-mercaptoethanol
y 75 μl bromophenol blue). Finally, cadherins and catenins
were detected by Western blot.
Rho pull down assay
GTP-bound Rho GTPase was pulled down with rhotekin
RBD protein GST beads (Cytoskeleton Inc, Denver, CO)
according to the manufacturer’s instructions from cell
lysates of A375 cells untreated or treated for 48 h with
HDACi. Cells were lysed in PIPES 50 mM at pH 7
(0.130 mM NaCl, 1 mM PMSF, 1 mM DTT, 5 μl/ml
leupeptin and 0,5 % Triton X-100). Later, samples were
diluted to 0.5 mg/ml in lysis buffer (50 mM Tris pH 7.5,
10 mM MgCl2, 0.3 M NaCl, 2 % IGEPAL) with a protease
inhibitor cocktail. Samples were centrifuged at 14,000 rpm
at 4 °C for 15 min and 1/10th volume of loading buffer
was added (150 mM EDTA). GTPγS 0.2 mM and GDP
1 mM were added to two control lysates as positive and
negative control respectively.
Samples were incubated 15 min at room temperature
and reaction was stopped with stop buffer (600 mMMgCl2)
to a final concentration of 60 mM. Then, protein beads
were resuspended, 20 μl were added to each tube, and
gently rotated at 4 °C for 1 h. Beads were washed twice with
500 μl of wash buffer (25 mM Tris pH 7.5, 30 mM MgCl2,
40 mM NaCl) and centrifuged at 5000 rpm for 1 min a
4 °C. Finally, beads were resuspended in SDS buffer and
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analyzed by Western Blot using a RhoA specific monoclo-
nal antibody.
Expression constructs
HT-144 cells were cotransfected with two vectors encoding
RhoA dominant negative (RhoA-T19N) and the green
fluorescent protein (GFP) at a 5:1 ratio. 48 h after transfec-
tion, the percentage of GFP expressing cells was analyzed
by flow cytometry to evaluate transfection efficiency. Trans-
fection was performed using Xfect (Clontech) following the
manufacturer’s instructions. The collagen invasion assay
was performed 48 h after transfection.
Antibodies
Antibodies against E-cadherin (HECD1) and RhoA were
acquired from Takara and Upstate respectively. Antibodies
for α-catenin and N-cadherin were purchased from Sigma.
The neutralizing antibody against N-cadherin GC-4 was
also acquired from Sigma.
Gene silencing
2,5×105 HT-144 cells were plated in 6-well plates and 24 h
later transfected with iRNAmax Lipofectamine and siRNAs
targeting N-cadherin [30], purchased to Qiagen: Inhibition
of N-cadherin expression was achieved by RNA interfe-
rence using a 1:1 mixture of the following double-stranded
oligoribonucleotides (1,5 μl each from 10 μM solution in
9 μl of Lipofectamine): siN-CAD2 5-AGUGGCAAGUGG
CAGUAAA-3 and siN-CAD3 5-GGAGUCAGCAGAAGU
UGAA-3’. To verify the specificity of the silencing effect
we also used a sequence with no known mammalian
target as a control (con 5-UUCUCCGAACGUGUCACG
U-3). Forty-eight hours after transfection collagen inva-
sion assays were performed in the same conditions as
those used with no transfected cells. Cells lysates were
obtained to confirm silencing.
Statistical analysis
Values in the figures are expressed as means ± S.D. Stat-
istical analyses were conducted using the Student t-test
for the comparison of two data groups with GraphPad
(Prism4).
Results
HDACi sensitivity assay
Cells were treated for 24 h with varying concentrations of
Butyrate (1, 2, 4, 8 and 16 mM), TSA (50, 100, 200, 300
and 400 nM), Valproic acid (0.5, 1, 2, 4 and 8 mM) and
Vorinostat (1.5, 3, 6, 12 and 24 μM). Viable cell numbers
were determined by colorimetric assay, and plotted rela-
tive to untreated control cells (Fig. 1). At the concentra-
tions selected for the invasion assays HDACi reduced the
number of viable cells in both A375 (by 3–15 %) and HT-
144 (by 13–25 %) melanoma cells. HT-144 cells were
more sensitive to all HDACi than A375 cells (Fig. 1).
HDACi induce melanoma invasion in Matrigel and type I
collagen
In order to elucidate the role of HDACi in the invasive
ability of melanoma cells, we have tested the effect of four
different HDACi on A375 and HT-144 melanoma cell lines
using Matrigel and type I collagen invasion assays. Our
results show that A375 cell invasion is significantly
increased in Matrigel when treated with butyrate, TSA,
valproic acid or vorinostat during 24 h (p < 0.001) (Fig. 2 a).
In contrast, HT-144 cells treated with butyrate (p < 0.01),
TSA (p < 0.001) and vorinostat (p < 0.001) show signifi-
cantly higher invasion into type I collagen when compared
to untreated cultures (Fig. 2 c). Nevertheless, HT-144
cell invasiveness does not undergo significant changes in
response to valproic acid (Fig. 2 c).
HDACi induce apoptosis in melanoma cells
To analyze the induction of apoptosis by the HDACi at
the selected concentrations we determined the number of
Annexin V stained cells after 24 and 48 h of treatment.
The number of cells undergoing apoptosis at 24 h in the
untreated A375 culture was 11.7 %, this value was similar,
or even lower, in the cultures treated with TSA (10.4 %)
and valproic acid (7.4 %) but it was slightly increased with
butyrate (17.2 %) and vorinostat (15.3 %). The effect of
HDACi on apoptosis induction was higher after 48 h, the
basal level of apoptotic cells observed in the untreated
A375 cells (12.6 %) was significantly increased in the cul-
tures treated with butyrate (18.1 %), valproic acid (20.4 %)
and vorinostat (27 %). TSA (11 %) was the only inhibitor
that did not show significant changes in the apoptosis
levels after 48 h.
HDACi treatment leads to changes in HT-144 melanoma
cell morphotype
After 24 h of treatment with any of the different HDACi,
HT-144 cells exhibited a more elongated shape than their
untreated counterparts (Fig. 3). In untreated cultures,
HT-144 cells were mostly round-shaped and just about
20 % of the cells appear slightly elongated. However, the
proportion of elongated cells increased up to 75 % after
exposure to HDACi. We also observed that the intensity
of the effect of each inhibitor on the morphology of mela-
noma cells was heterogeneous. Thus, butyrate and valproic
acid induced subtle cell elongation at 24 h, while TSA and
vorinostat had a dramatic effect on the morphotype, with
the presence of long projections and mesenchymal-like cell
appearance. Shape factor, which is around 0.8 in the
control, decreased to almost 0.3 in the presence of some
of the inhibitors. TSA and vorinostat had the strongest
effect on shape factor with average values of 0.34 and 0.42
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respectively, whereas butyrate (0.62) elicited a milder
response. In contrast, valproic acid was the only inhibitor
that did not induce a significant effect on shape factor. It
should be taken into account that the percentage of elon-
gated cells differed among the different treatments. Thus, it
was around 40 % in butyrate or TSA treated cultures
whereas it reached 80 % of total cells in response to
vorinostat.
HDAC inhibitors increase N-cadherin expression in
melanoma cells
The switch from E-cadherin to the mesenchymal cell
associated N-cadherin has often been observed during
cancer progression. Therefore, the expression of both
E- and N-cadherin was analyzed by Western blot in
HT-144 and A375 cell lines treated with HDACi. The
expression of the two analyzed cadherins was signifi-
cantly increased in both cell lines in response to 24 h
treatments with butyrate and valproic acid, with a re-
markable effect on HT-144 cells (Fig. 4). In contrast,
TSA and vorinostat had a very slight or null effect on
cadherin expression levels.
In order to analyze the functionality of E- and N-cad
herin, we determined their association with α-catenin
through immunoprecipitation (Fig. 5). Our results show
that, even though the expression of total E-cadherin is
up-regulated by butyrate and valproic acid, these inhibi-
tors induce a switch from E-cadherin to N-cadherin in
the association with the α-actin cytoskeleton through
α-catenin. The increase of α-catenin-associated N-cadherin
is especially relevant in melanoma cells treated with sodium
butyrate.
The inhibition of N-cadherin abrogates HDACi induced
invasion
To demonstrate the direct implication of N-cadherin in
HDACi-induced invasion, we performed collagen invasion
assays with melanoma cells treated with butyrate, TSA
and vorinostat, while blocking N-cadherin with an anti-N-
cadherin monoclonal antibody (GC-4 mAb) (Fig. 6 a). In
these experiments, the pro-invasive effect of the HDACi
was completely abrogated when the blocking antibody
was added to the culture medium. Additionally, the silen-
cing of N-cadherin using specific siRNA in HT-144 cells
Fig. 2 Invasion assays. a Matrigel invasion assay with the A375 cell line. Cells were treated with butyrate, TSA, Valproic acid and Vorinostat during 24 h.
All HDACi significantly increased melanoma cell invasion. b Confocal microscopy of the transwell membrane with A375 cells stained with Hoechst,
corresponding to control (left) and butyrate treatment (right) from Matrigel invasion assay. Scale bar, 500 μm. c Type I collagen invasion assay with
HT-144 cell line. Cells were treated with the same agents as in (a) for 24 h. Butyrate, TSA and Vorinostat induced a significant increase on invasion,
whereas Valproic acid had no effect. d Contrast phase microscopy of HT-144 cells on collagen gel, corresponding to control (left) and vorinostat
(right) after 24 h treatment. Scale bar, 50 μm. Statistically significant differences from control; ***p < 0.001, ** p < 0.01 and * p < 0.05. Abbreviations:
But, butyrate; TSA, Trichostatin A; VPA, Valproic acid; Vor, Vorinostat
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abrogates the butyrate-induced invasion in a similar way to
that observed with blocking antibodies, which constitutes
an additional evidence for N-cadherin to be a mediator of
HDACi-induced invasion. Interestingly, neither the block-
ing antibodies nor the siRNA have any effect on melanoma
cell basal invasion (Fig. 6 b). This result suggests that
the basal invasion observed in untreated cells does not
depend on N-cadherin and that the proinvasive effect
of HDACi might be due to some signaling triggered
by the disturbance of the cadherin balance in favor to
N-cadherin.
RhoA downregulation induces HT-144 cell invasion
In order to evaluate the possible role of small GTPases in
the pro-invasive activity of HDACi, we performed a pull
down assay for active RhoA in cell lysates from A375 cells
untreated or treated for 48 h with HDACi. Our results
show that there is a significant downregulation of active
RhoA when cells are treated with butyrate, TSA and
vorinostat (Fig. 7a), whereas a slight inhibition is observed
with valproic acid.
Subsequently, we analyzed the role of the Rho/ROCK
pathway in the invasive ability of melanoma cells. To this
Fig. 3 Morphological changes induced by HDACi. a Phalloidin stained HT-144 cells growing in collagen gel after a 24 h treatment with butyrate,
TSA, Valproic acid and Vorinostat. b SEM images of A375 invading cells treated with the same agents. All HDACi provoked morphological changes in
melanoma cells, which in particular, appeared to be more elongated. c Shape factor, which is around 0.8 in the control, decreases to almost 0.3 with
some of the inhibitors. Cells treated with valproic acid did not show a significant decrease in shape factor compared to control. Statistically significant
differences from control: ***p < 0.001, ** p < 0.01 and * p < 0.05. Abbreviations: But, butyrate; TSA, Trichostatin A; VPA, valproic acid; Vor, vorinostat
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end, we performed a collagen invasion assay adding the
Rho and ROCK inhibitors C3T and Y-27632, respectively.
Both inhibitors emulate the pro-invasive effect of HDACi
(Fig. 7 b). The collagen invasion assays performed using
HT-144 cells transfected with dominant-negative RhoA
(T19N) yielded similar results, confirming that the down-
regulation of RhoA mimics the effects of HDACi in
HT-144 cells.
Discussion
Alterations in cell–cell adhesion, cytoskeleton reorganiza-
tion and the acquisition of mesenchymal cell morphology
Fig. 4 Western Blot analysis of E-cadherin and N-cadherin in HT-144 and A375 melanoma cell lines treated with HDACi during 24 h. Figure shows
images from a representative experiment. Both E- and N-cadherin upregulation was observed in the two cell lines, specially with butyrate and
valproic acid. Vimentin expression was induced by the four inhibitors in A375 cells but only butyrate had a significant effect on HT-144 cell line.
Tubulin was used as a loading control to normalize protein content. Abbreviations: But, butyrate; TSA, Trichostatin A; VPA, valproic acid; Vor, vorinostat.
Fig. 5 Immunoprecipitation with α-catenin. Western blot of HT-144 extracts (control and treated with HDACi for 24 h) to detect E-cadherin and
N-cadherin immunoprecipitated with α-catenin. Graphs show relative intensity from E-cadherin/ α-catenin and N-caherin/ α-catenin, numeric data
was obtained by densitometry (ImageJ). Abbreviations: But, butyrate; TSA, Trichostatin A; VPA, valproic acid; Vor, vorinostat
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are processes frequently observed during embryonic devel-
opment, wound healing and several diseases, including can-
cer [31, 32]. These modifications may promote carcinoma
cells to acquire invasion ability, which constitutes a critical
step in tumor malignancy and metastasis [33, 34]. The
E- to N-cadherin switch has been related to increased cell
invasion, tumor progression and metastasis in melanoma
and other carcinomas [30, 35–37].
Rho GTPase, which plays an important role in the regu-
lation of the actin cytoskeleton, has also been associated
with cancer invasion [38, 39]. Nevertheless, its role in
tumor progression is still not clear, since the increased cell
invasiveness has been associated with both the activation
and the inhibition of Rho [30, 40–42].
The acetylation/deacetylation of chromosomal histones,
regulated by HDACs and HATs, is an important epigenetic
mechanism involved in the regulation of gene expression
[43]. Currently, HDACi appear as promising antitumor
drugs due to their ability to suppress proliferation and
induce apoptosis [2, 44]. Nevertheless, there is some con-
troversy about how HDACi affect the invasive potential of
cancer cells. Some studies describe an anti-invasive activity
of HDACi [2, 18–20, 44] whereas other authors affirm that
these inhibitors increase invasion in several cancer cell lines
[10, 21].
In the present study, we have demonstrated that several
HDACi induce the up-regulation of N-cadherin and a
significant inhibition of Rho activity in melanoma cell lines.
Moreover, all these modifications lead to an increased inva-
siveness of melanoma cells into Matrigel and type I colla-
gen matrices. Of the four HDACi examined, Butyrate, TSA
and vorinostat are the most effective in inducing melanoma
invasion; valproic acid show a pro-invasive activity on A375
but fail to induce invasion in HT-144. These results corre-
late with the modifications in the adhesion molecules and
Rho activity observed in the HDACi treated cells. Butyrate,
TSA and vorinostat significantly inhibit the activity of RhoA
in melanoma cells, whereas valproic acid does not produce
significant changes in this parameter. The distinct effects of
Rho inhibition on cancer cell invasion has been related to
the expression of its different isoforms [45] and the activity
of the zinc-finger transcription factors Snai1 and Snail2
[41]. Moreover, it has been demonstrated that the down-
regulation of Rho GTPase activity is able to induce collec-
tive cell migration through the stimulation of filopodia
formation [42], in line with our morphological observations
of HDACi treated melanoma cells. In this study we have
also shown that the inhibition of the Rho/ROCK pathway
by specific inhibitors or dominant-negative RhoA transfec-
tion leads to the same pro-invasive effect obtained with
HDACi. This result suggests a direct implication of this
pathway in the melanoma response to HDACi treatments.
Butyrate, TSA, valproic acid and vorinostat increase the
association of N-cadherin with α-catenin, and thus, with
the actin cytoskeleton. Butyrate does not alter the levels of
E-cadherin linked to α-catenin, but does lead to the highest
upregulation of functional N-cadherin. The effect of TSA
and valproic acid on N-cadherin is lower than the effect of
butyrate. However, they produce a significant downregu-
lation of the E-cadherin association to alpha catenin.
Surprisingly, vorinostat increases the association of both
E-cadherin and N-cadherin to alpha catenin. Nevertheless,
the dominance of the N-cadherin derived phenotype when
the two cadherins are present has been previously demon-
strated [46]. In the present study we demonstrate that the
pro-invasive effect of butyrate, TSA and vorinostat on
melanoma cells is completely abrogated through the
inhibition of N-cadherin by a specific blocking antibody
and siRNA. It is also noteworthy that several studies indi-
cate that cadherin-mediated cell-cell adhesion and Rho
small GTPase activity are reciprocally modulated [47, 48].
As we have previously mentioned, it is intriguing that the
basal melanoma invasion observed in control cultures are
not reduced by any of the methods used for N-cadherin
inhibition. Our hypothesis is that this basal invasion is
N-cadherin independent and that the increase in melanoma
Fig. 6 a Collagen invasion assay with HT-144 treated with the GC-4
antibody to block N-cadherin. When N-cadherin was blocked with
GC-4 the pro-invasive effect of butyrate, TSA and Vorinostat was
reverted. b HT-144 cells 48 h after silencing with negative control
siRNA and N-cadherin (with and without butyrate) (c) Western Blot
analysis of N-cadherin in negative control and N-cadherin siRNA
transfected cells. *** Statistically significant difference from
control, p < 0.001
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cell invasion in response to HDACi might be the result of
some kind of signaling pathway triggered by the distur-
bance of the cadherin balance in favor to N-cadherin.
Further research should be done in order to identify the
mechanisms involved in this process. The identification of
these mechanisms could help to understand the differences
observed between Matrigel and collagen invasion assays,
what could be related with the different composition of
these ECM. Our results show that the proinvasive effect of
HDACi is more effective on Matrigel than in collagen type
I, what suggests that cell-matrix adhesion molecules with
higher affinity for laminin or collagen type IV could be
involved in the invasion process.
Taken all together, our results indicate that the hetero-
geneity of the melanoma cell response to the different
HDACi, especially evident in HT-144 cells, is the result
of a balance between the pro-apoptotic and pro-invasive
effects of these drugs. We have found a reduction in the
number of viable melanoma cells treated with HDACi
which ranges from 3 to 25 %. This reduction is due to the
combination of the well-known HDACi induced cell cycle
arrest [17, 49] and the induction of apoptosis, which we
have shown to be slightly increased after 24 h of exposure
to the drugs. Accordingly, the failure of valproic acid to
increase the number of invasive HT-144 cells in the
collagen invasion assay could be partially explained by the
significant reduction of viable HT-144 cell numbers pro-
duced by this drug, which also fails to inhibit the activity
of RhoA. On the other hand, vorinostat had a antiprolifer-
ative effect which was similar to that of valproic acid on
HT-144 cells but, at the same time, it produced the high-
est pro-invasive response in these cells. This apparently
contradictory result could be explained by its very effec-
tive inhibition of the RhoA GTPase activity. Thus, the
effect of HDACi on melanoma cell invasion is likely the
result of a combination of several modifications in cell
homeostasis in addition to apopotisis, N-cadherin induc-
tion or RhoA inhibition. Further research would be useful
to clarify this issue.
Conclusions
HDACi are currently in use in clinical trials against several
cancer types [50]. Our results have demonstrated that
HDACi induce melanoma cell invasion in vitro. According
to the present study, the use of HDACi in melanoma pa-
tients could facilitate metastasis through the up-regulation
of N-cadherin and the inhibition of RhoA activity. This
finding sheds light on our understanding of the role of
Fig. 7 Rho implication in HDACi induced invasion. a Active Rho pull down assay in A375 melanoma cells treated for 48 h with HDACi. Butyrate, TSA,
Valproic acid and Vorinostat promoted active Rho downregulation. b Collagen invasion assay using Rho inhibitor C3T and ROCK inhibitor Y27. c HT
−144 cells transfected with dominant negative for RhoA-T19N plasmid. Both inhibitors emulated the effect of HDACi on HT-144 invasion, as well as
Rho downregulation by transfection. d Transfection efficiency measured as GFP transfected cells in cytometry. e GFP transfected cells as seen with
fluorescence microscopy. *** Statistically significant difference from control, p < 0.001
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HDACi in tumor progression, but it also warrants caution
regarding the use of these agents in the treatment of mela-
noma. Further investigations into the effects of HDACi
should be carried out to elucidate the molecular mecha-
nisms underlying their pro-invasive effects on melanoma
cells. These investigations may provide the necessary
insight to neutralize the potentially adverse effects of
HDACi.
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